TSHA · Forms 3, 4, 5
Insider trades at Taysha Gene Therapies, Inc.
No open-market insider buys or sells at Taysha Gene Therapies, Inc. in the last 90 days; 10 filings reported awards, option exercises, tax withholding or new insiders.
Every Form 3, 4 and 5 filed for Taysha Gene Therapies, Inc. (TSHA) with the SEC, newest first: who traded, their role, buy or sell, shares, price and value.
Most recent insider filings
No Form 3, 4 or 5 filings for Taysha Gene Therapies, Inc. in the last 90 days. The latest ones on EDGAR:
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sukumar Nagendran | President and Head of R&D | Sell (10b5-1 plan) | 200,000 | $6.24 | $1.2M | Form 4 | |
| John A Stalfort III | Director | Award | 21,335 | Form 4 | |||
| Phillip B. Donenberg | Director | Award | 21,335 | Form 4 | |||
| Alison S Long | Director | Award | 21,335 | Form 4 | |||
| Laura Sepp-Lorenzino | Director | Award | 21,335 | Form 4 | |||
| Sukumar Nagendran | President and Head of R&D | Option exercise | 19,021 | $1.71 | $33K | Form 4 | |
| Sukumar Nagendran | President and Head of R&D | Sell (10b5-1 plan) | 200,000 | $4.46 | $892K | Form 4 | |
| Kamran Alam | CHIEF FINANCIAL OFFICER | Sell | 1,655 | $4.52 | $7K | Form 4 | |
| Sukumar Nagendran | President and Head of R&D | Sell | 26,918 | $4.61 | $124K | Form 4 | |
| Sean P. Nolan | Chief Executive Officer | Sell | 41,312 | $4.61 | $190K | Form 4 | |
| Kamran Alam | CHIEF FINANCIAL OFFICER | Sell | 23,849 | $4.61 | $110K | Form 4 | |
| Sukumar Nagendran | President and Head of R&D | Sell | 89,132 | $4.75 | $423K | Form 4 | |
| Sean P. Nolan | Chief Executive Officer | Sell | 136,789 | $4.75 | $650K | Form 4 | |
| Kamran Alam | CHIEF FINANCIAL OFFICER | Sell | 78,968 | $4.75 | $375K | Form 4 |
Buy and Sell are open-market purchases and sales (transaction codes P and S), the trades investors watch. Awards, option exercises, tax withholding and gifts are reported too but are not market trades.